Welcome to our dedicated page for Palatin Tech SEC filings (Ticker: PTN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Palatin Technologies filings document regulatory disclosures for a biopharmaceutical company developing melanocortin receptor-targeted drug candidates. Its 8-K reports and proxy materials cover capital-structure actions, including a 1-for-50 reverse stock split, warrant-share issuance approvals, equity incentive plan matters and listing or trading-status notices for the company’s common stock.
The filing record also includes material-event disclosure on a research collaboration, license and patent assignment agreement with Boehringer Ingelheim for retinal disease programs, annual meeting voting results, advisory executive-compensation votes, corporate governance matters, operating and financial results, and clinical or regulatory disclosures tied to Palatin’s development pipeline.
Janus Henderson Group plc has disclosed a significant ownership position in Palatin Technologies, Inc. common stock. The filing reports beneficial ownership of 170,097 shares, representing 9.99% of Palatin’s common stock, including certain pre-funded and common stock warrants that are exercisable within 60 days but subject to a 9.99% beneficial ownership cap.
The disclosure notes that, because of this cap, an additional 8,562 pre-funded warrants and 182,000 Series J and 182,000 Series K common warrants are not included in the reported figures. A related reporting person, Janus Henderson Biotech Innovation Master Fund Ltd, is shown as beneficially owning 118,196 shares, or 6.6% of the class, with shared voting and dispositive power. The securities are certified as being held in the ordinary course of business and not for the purpose of changing or influencing control of Palatin.
Palatin Technologies, Inc. reported an insider ownership update for its President and CEO on a Form 4. On November 14, 2025, the executive had shares of common stock withheld by the company to cover employee payroll tax obligations tied to previously granted stock awards. The reported withholding transactions covered 51, 33, 119, and 142 shares from separate vesting grants, at per-share values determined on their respective vesting dates in June 2025. After these tax-withholding transactions, the executive directly beneficially owned 33,113 shares of Palatin common stock.
Palatin Technologies, Inc. reports that NYSE American has determined its common stock is no longer suitable for listing under Section 1003(f)(v) of the NYSE American Company Guide because of the stock’s low selling price, and NYSE American has commenced delisting proceedings. Trading of the common stock on NYSE American was suspended on May 7, 2025. The common stock has traded on the OTCQB Market of the OTC Markets Group, initially under the symbol “PTNT”, then under “PTNTD” beginning August 12, 2025, for a twenty trading day period following a 1-for-50 reverse stock split. Effective September 10, 2025, the common stock again trades on the OTCQB Market under the symbol “PTNT”.
Palatin Technologies, Inc. entered into a Research Collaboration, License and Patent Assignment Agreement with Boehringer Ingelheim International GmbH to develop melanocortin receptor-targeted peptides for retinal diseases, including diabetic retinopathy. Palatin will assign certain patent rights, collaborate on research at Boehringer Ingelheim’s expense for two years (with a possible six‑month extension), and is entitled to an upfront payment of €2.0 million ($2.3 million), up to €18.0 million ($20.9 million) in near‑term research milestones, and up to €260 million ($301.6 million) in development, regulatory and commercial milestones, plus tiered sales royalties subject to specified reductions. The agreement runs on a product‑by‑product, country‑by‑country basis through the applicable royalty term, with termination rights for bankruptcy or material breach and with Boehringer Ingelheim also able to terminate for any reason after a notice period. Separately, Palatin’s common stock was determined no longer suitable for listing on NYSE American due to its low selling price and now trades on OTC Markets under the symbol PTNTD.
Palatin Technologies, Inc. will implement a 1-for-50 reverse stock split approved by shareholders and the board, expected to become effective after market on August 11, 2025, with shares trading on a split-adjusted basis on the OTCQB at market open on August 12, 2025. The company was previously determined not suitable for NYSE American listing due to a low selling price; trading was suspended May 7, 2025, and the stock has since traded on OTC Pink and then OTCQB under the symbol PTNT. The timing change reflects a delayed FINRA approval now expected after market on August 11, 2025.
Palatin Technologies completed a 1-for-50 reverse stock split approved by shareholders, effective August 8, 2025 at 5:00 p.m. ET. The action combines every 50 shares into one share while leaving the par value and other terms unchanged. Shares are expected to trade on the OTCQB on a split-adjusted basis beginning August 11, 2025 and will use the temporary ticker PTNTD for 20 trading days.
The company disclosed that NYSE American determined the common stock was no longer suitable for listing due to a low selling price and commenced delisting proceedings, with trading suspended on May 7, 2025. The stock traded on the Pink Market May 8–June 6, 2025 and has traded on the OTCQB since June 9, 2025. Fractional shares will be paid in cash based on the five-day average closing price prior to August 8, 2025.